All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
MicroRNAs (miRNAs) are single stranded, small, non-coding RNAs which are known to play an important role in many biological processes and are detectable in serum and plasma samples. Aberrant expression of several miRNAs (miR-155, miR-210, miR-126-5p, miR-370, miR-328, and miR-204) have been associated with outcome in acute myeloid leukemia (AML).1-6 Recently, low serum expression of miR-223 has been implicated in the development of AML.7-9
Guopan Yu, Nanfang Hospital, Guangzhou, CN, and team compared serum levels of miR-223 in 131 patients with AML and 70 healthy controls who had no cancer symptoms or clinical signs of any other disease.10 RNA was extracted from serum and reverse transcribed prior to quantitative real time polymerase chain reaction (qPCR) being performed for both miR-223 and for a control miRNA that had been spiked into the sample at a known concentration during RNA purification.
Patients (n= 131) |
Low miR-223 (n= 69) |
High miR-223 (n= 62) |
p value |
|
---|---|---|---|---|
Cytogenetics Favorable Intermediate Unfavorable |
52 61 18 |
16 38 15 |
36 23 3 |
< 0.0001 |
Complete remission Yes No |
55 76 |
20 49 |
35 27 |
0.0015 |
Blasts in bone marrow < 50% ≥ 50% |
54 77 |
21 48 |
33 29 |
0.0081 |
Guopan Yu and colleagues state that their work is in agreement with previous work on miR-223 in AML.7-9 miR-223 regulates the equilibrium between expansion and differentiation in hematopoietic stem and progenitor cells, and expression of miR-223 leads to the production of red blood cells, T cells and B cells. Expression of miR-223 inhibits cell proliferation and increases apoptosis in AML cell lines, and knocking down miR-223 increases the frequency of myeloid progenitors. The authors discussed how decreased expression of miR-223 seems to be associated with nasopharyngeal carcinoma, cervical cancer, gallbladder cancer, hepatocellular carcinoma, and breast cancer, yet increased expression is seen in gastric cancer, colon cancer, and non-small cell lung cancer.10 The group conclude that miR-223 may be able to be used as diagnostic tool and as a predictor of poor patient outcome in patients with AML.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox